BioCentury
ARTICLE | Company News

GlaxoSmithKline other news

January 6, 2014 8:00 AM UTC

GlaxoSmithKline announced on Dec. 18, 2013, a $1 million prize to be awarded to the first scientists who create a miniature, fully implantable device that can read, write and block the body's electrical signals to treat disease. GSK said parameters for the challenge will be available online on Feb. 1. The challenge was created by attendees of a summit held by GSK's Bioelectronics R&D unit in December. Bioelectronics, or electroceuticals, is an emerging class of therapeutics that consist of nanoscale electrical circuits delivered to specific tissues by implantation or targeted delivery. In August, GSK said bioelectronics can be designed to "interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses" to treat disorders like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and respiratory and metabolic disorders, such as Type II diabetes. ...